Lubiprostone for chronic idiopathic constipation and irritable bowel syndrome with constipation

Expert Review of Gastroenterology and Hepatology

Volumn 2, Issue 4, 2008, Pages 497-508

  Saad, Richard ^a   Chey, William D ^b  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Chloride channel; Constipation; Irritable bowel syndrome; Lubiprostone

Indexed keywords

CHLORIDE CHANNEL; ISPAGULA; LAXATIVE; LUBIPROSTONE;

ABDOMINAL PAIN; ARTICLE; CHRONIC DISEASE; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DIET THERAPY; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG APPROVAL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; GASTROINTESTINAL SYMPTOM; HUMAN; IDIOPATHIC DISEASE; LIFESTYLE MODIFICATION; NAUSEA; NONHUMAN; PATIENT COMPLIANCE; POSTMARKETING SURVEILLANCE; PREVALENCE; QUALITY OF LIFE; REBOUND; RECOMMENDED DRUG DOSE; SINGLE DRUG DOSE; STRUCTURE ANALYSIS; TREATMENT DURATION;

ALPROSTADIL; CHLORIDE CHANNELS; CHRONIC DISEASE; CONSTIPATION; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; IRRITABLE BOWEL SYNDROME;

EID: 55649098147     PISSN: 17474124     EISSN: None     Source Type: Journal    
DOI: 10.1586/17474124.2.4.497     Document Type: Article

References (49)

1. Higgins PD, Johanson JF. Epidemiology of constipation in North America: a systematic review. Am. J. Gastroenterol. 99(4), 750-759 (2004).
2. Shah N, Locke GR 3rd, Meek P, Chitkara D, Talley NJ. Ambulatory care for constipation in the United States, 1997-2004. Am. J. Gastroenterol. 101(S2), S220 (2006).
3. Rantis PC Jr, Vernava AM 3rd, Daniel GL, Longo WE. Chronic constipation - is the work-up worth the cost? Dis. Colon Rectum 40(3), 280-286 (1997).
4. Brook R, Kleinman N, Melkonian A, Baran R. Cost of illness for constipation: medical pharmacy, and work absence costs in employees with or without constipation. Am. J. Gastroenterol. 101(S2), S408 (2006).
5. Kleinman N, Brook R, Melkonian A, Baran R. Assessment of work absences associated with constipation. Am. J. Gastroenterol. 101(Suppl. 2), S409 (2006).
6. Dennison C, Prasad M, Lloyd A, Bhattacharyya SK, Dhawan R, Coyne K. The health-related quality of life and economic burden of constipation. Pharmacoeconomics 23 (5), 461-476 (2005).
7. An evidence-based approach to the management of chronic constipation in North America. Am. J. Gastroenterol. 100(Suppl. 1), S1-S4 (2005).
8. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology 130(5), 1480-1491 (2006).
9. Lembo A, Camilleri M. Chronic constipation. N. Engl. J. Med. 349(14), 1360-1368 (2003).
10. Rao SS. Constipation: evaluation and treatment of colonic and anorectal motility disorders. Gastronenterol. Clin. N. Am. 36(3), 687-711 (2007),
11. Mertz H, Naliboff B, Mayer E. Physiology of refractory chronic constipation. Am. J. Gastroenterol. 94(3), 609-615 (1999).
12. Johanson JF, Kralstein J. Chronic constipation: a survey of the patient perspective. Aliment. Pharmacol. Ther. 25(5), 599-608 (2007).
13. Ramkumar D, Ran SS. Efficacy and safety of traditional medical therapies for chronic constipation: systematic review. Am. J. Gastroenterol. 100(4), 936-971 (2005).
14. Brandt LJ, Prather CM, Quigley EM, Schiller LR, Schoenfeld P, Talley NJ. Systematic review on the management of chronic constipation in North America. Am. J. Gastroenterol. 100(Suppl. 1), S5-S21 (2005).
15. Schoenfeld P. Efficacy of current drug therapies in irritable bowel syndrome: what works and does not work. GastronenteroL Clin. N. Am. 34(2), 319-335, viii (2005).
16. Suzuki M, Morita T, Iwamoto T. Diversity of Cl(-) channels. Cell Mol. Life Sci. 63(1), 12-24 (2006).
17. Zifarelli G, Pusch M. CLC chloride channels and transporters: a biophysical and physiological perspective. Rev. Physiol. Biochem. Pharmacol. 158, 23-76 (2007).
18. Lipecka J, Bali M, Thomas A, Fanen P, Edelman A, Fritsch J. Distribution of CIC-2 chloride channel in rat and human epithelial tissues. Am. J. Physiol. 282(4), C805-816 (2002).
19. Lacy BE, Levy LC. Lubiprostone: a chloride channel activator. J. Clin. Gastroenterol. 41(4), 345-351 (2007).
20. Cuppoletti J, Malinowska DH, Tewari KP et al. SPI-0211 activates T84 cell chloride transport and recombinant human CIC-2 chloride currents. Am. J. Physiol. 287(5), C1173-C1183 (2004).
21. Ueno R, Osama H, Habe T, Engelke K, Patchen ML. Oral SPI-0211 increases intestinal fluid secretion and chloride concentration wihtout altering serum electrolyte levels. Gastroenterology 126(4 Suppl. 2), A298 (2004) (Abstract).
22. Perentesis G, Crawford D, Engelke K, Osama H, Ueno R. Effects of lubiprostone, a novel GI chloride channel activator, on isolated smooth muscle. Neurogastroenterol. Motility 17(5), 625-626 (2005) (Abstract).
23. Bassil AK, Borman RA, Jarvie EM et al. Activation of prostaglandin EP receptors by lubiprostone in rat and human stomach and colon. Br. J. Pharmacol. 154(1), 126-135 (2008).
24. Amitiza® (lubiprostone), prescribing information. Sucampo Pharmaceuticals Inc. (2007).
25. Crawford D, Perentesis G, Engelke K, Kawai R, Ueno R. Pharmacokinetic profile of lubiprostone, a selective GI chloride channel activator after a single oral dose in multiple animal species. Am. J. Gastroenterol. 100(S9), S330 (2005) (Abstract).
26. Ueno R. Multiple, escalating, oral-dose study to assess the safety, tolerance and pharmacodynamic profile of lubiprostone in normal healthy volunteers. Neurogastroenterol. Motility 17(4), 626 (2005) (Abstract).
27. Camilleri M, Bharucha AE, Ueno R et al. Effect of a selective chloride channel activator, lubiprostone, on gastrointestinal transit, gastric sensory, and motor functions in healthy volunteers. Am. J. Physiol. Gastrointest. Liver Physiol. 290(5), G942-G947 (2006).
28. Johanson JF, Ueno R. Lubiprostone, a locally acting chloride channel activator, in adult patients with chronic constipation: a double-blind, placebo-controlled, dose-ranging study to evaluate efficacy and safety. Aliment. Pharmacol. Ther. 25(11), 1351-1361 (2007).
29. Johanson JF, Morton D, Geenen J, Ueno R. Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of lubiprostone, a locally-acting type-2 chloride channel activator, in patients with chronic constipation. Am. J. Gastroenterol. 103 (1), 170-177 (2008).
30. Johanson JF, Gargano MA, Holland PC, Patchen ML, Ueno R. Initial and sustained effects of lubiprostone, a chloride channel-2 (CIC-2) activator for the treatment of constipation: data from a 4-week Phase III study. Am. J. Gastroenterol. 100(s9), S324-325 (2005) (Abstract).
31. Johanson JF, Gargano MA, Holland PC, Patchen ML, Ueno R. Phase III study of lubiprostone, a chloride channel-2 (CIC-2) activator, for the treatment of constipation: safety and primary efficacy. Am. J. Gastroenterol. 100(S9), S328-S329 (2005) (Abstract).
32. Johanson JF, Gargano MA, Holland PC, Patchen ML, Ueno R. Phase III, randomized withdrawal study of RU-0211, a novel chloride channel activator for the treatment of constipation. Gastroenterology 126(4 Suppl. 2), A100 (2004) (Abstract).
33. Johanson JF, Gargano MA, Holland PC, Patchen ML, Ueno R. Multicenter open-label study of oral lubiprostone for the treatment of chronic constipation. Am. J. Gastroenterol. 100(S9), S331 (2005) (Abstract).
34. Johanson JF, Panas R, Holland PC, Ueno R. Long-term efficacy of lubiprostone for the treatment of chronic constipation. Gastroenterology 130(4 Suppl. 2), A317 (2006) (Abstract).
35. Ueno R, Joswick TR, Wahle A, Zhu Y, Holland PC. Efficacy and safety of lubiprostone for the treatment of chronic constipation in elderly vs. non-elderly subjects. Gastroenterology 130(4 Suppl. 2), A189 (2006) (Abstract).
36. Ueno R, Panas R, Wahle A, Zhu Y, Holland PC. Long-term safety and efficacy of lubiprostone for the treatment of chronic constipation in elderly subjects. Gastroenterology 130(4 Suppl. 2), A188 (2006) (Abstract).
37. Ueno R, Joswick TR, Wahle A, Zhu Y, Holland PC. Efficacy and safety of lubiprostone for the treatment of chronic constipation in male vs. female subjects. Gastroenterology 130(4 Suppl. 2), A322 (2006) (Abstract).
38. Johanson JF, Drossman DA, Panas R, Wahle A, Ueno R. Clinical trial: Phase 2 study of lubiprostone for irritable bowel syndrome with constipation. Aliment. pharmacol. Ther. 27(8), 685-696 (2008).
39. Johanson JF, Wahle A, Ueno R. Efficacy and safety of lubiprostone in a subgroup of constipation patients diagnosed with irritable bowel syndrome with constipation (IBS-C). Am. J. Gastroenterol. 101(S2), S491 (2006) (Abstract).
40. Drossman DA, Chey WD, Panas R, Wahle A, Scott C, Ueno R. Lubiprostone significantly improves symptom relief rates in adults with irritable bowel syndrome and constipation (IBS-C): data from two twelve-week, randomized, placebo-controlled, double-blind trials. Gastroenterology 132(7), 2586-2587 (2007) (Abstract).
41. Chey WD, Drossman DA, Scott C, Panas R, Ueno R. Lubiprostone is effective and well tolerated through 48 weeks of treatment in adults with irritable bowel syndrome and constipation. Gastroenterology 134(4 Suppl. 1), A215 (2008) (Abstract).
42. Chey WD, Saad R, Panas R, Wahle A, Ueno R. Discontinuation of lubiprostone treatment for irritable bowel syndrome with constipation is not associated with symptom increase or recurrence: results from a randomized withdrawal study. Gastroenterology 134(4 Suppl. 1), A401 (2008) (Abstract).
43. Chey WD, Drossman DA, Scott C, Panas R, Ueno R. What symptoms drive global symptom improvement with lubiprostone in patients with irritable bowel syndrome and constipation: data from two multicenter, randomized, placebo-controlled trials. Gastroenterology 134(4 Suppl. 1), A28 (2008) (Abstract).
44. Drossman DA, Chey WD, Scott C, Panas R, Ueno R. Health-related quality of life in adults with irrkable bowel syndrome with constipation: results of a combined analysis of two Phase 3 studies with lubiprostone. Gastroenterology 134(4 Suppl. 1), A469 (2008) (Abstract).
45. Sprenger C, Copa A, Morganroth J, Panas R, Ueno R. Effect of lubiprostone, a unique agent for the treatment of chronic idiopathic constipation, on clinical electrocardiographic results. Gastroenterology 132(4 Suppl. 2), A325 (2007) (Abstract).
46. Rivera E, Wahle A, Joswick TR, Ueno R. Lubiprostone, a novel type-2 chloride channel (CIC-2) activator, does not affect serum electrolyte balance in elderly and nonelderly patients with chronic idiopathic constipation. Gastroenterology 132(4 Suppl. 2), A191 (2007) (Abstract).
47. Ueno R, Wahle A, Rivera E. Pooled analysis of the most frequent adverse events associated with the use of lubiprostone. Am. J. Gastroenterol. 101(s2), s489 (2006) (Abstract).
48. Engelke K, Harris S, Roerig B, Ueno R. Effect of lubiprpstone, a novel type-2 chloride channel (CIC-2) activator, in pregnant rhesus monkeys. Gastroenterology 132(4 Suppl. 2), A534 (2007) (Abstract).
49. Moeser AJ, Nighot PK, Engelke KJ, Ueno R, Blikslager AT. Recovery of mucosal barrier function in ischemic porcine ileum and colon is stimulated by a novel agonist of the CIC-2 chloride channel, lubiprostone. Am. J. Physiol. Gastrointest. Liver Physiol. 292(2), G647-656 (2007).